Shanghai Fosun Pharmaceutical (Group)

600196

The Outlook dimension in Gainify Rating assesses a stock’s growth potential by analyzing forward-looking metrics such as estimated 3-year Compound Annual Growth Rates (CAGR) for Revenue and Earnings Per Share (EPS), along with anticipated Gross Margin and other profitability ratios. These metrics provide insights into expected performance trends and profitability improvements over time. The stock’s growth potential is then compared to its peers and the broader market, helping gauge its competitive positioning in the industry.

The Valuation dimension in Gainify Rating examines a stock’s attractiveness by analyzing forward-looking valuation metrics, including Price-to-Earnings (P/E) Ratio, Price-to-Revenue (P/Revenue) Ratio, and Dividend Yield. These indicators offer insights into how the stock’s price aligns with its earnings, cash flow, revenue, and dividend returns, helping investors assess its relative value compared to peers and the broader market.

The Financial Health dimension in Gainify Rating assesses a company’s balance sheet stability and financial strength by analyzing debt and liquidity metrics. These indicators reveal how well-positioned the company is to manage debt, meet interest obligations, and maintain liquidity.

The Past Performance dimension in Gainify Rating looks at a stock’s historical growth and profitability over the last five years. It considers indicators like how well the company has used its capital to generate returns, how much its revenue and earnings have grown each year, and whether its stock price has shown steady growth. These factors help investors understand a company’s track record and consistency compared to others in its sector and the market overall.

The Price Momentum dimension in Gainify Rating evaluates a stock’s recent price strength and position relative to its historical highs, assessing short-term investor interest and potential upward or downward trends. It uses indicators such as the stock’s price change over the past 90 days, current price as a percentage of its 52-week high, and the 1-week Relative Strength Index (RSI).